Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Business Wire•28/10/2026•08:00 ET
0
Key Highlights
- ➤Coya (COYA) will present NfL-based ALS trial stratification methodology on October 28, 2026
- ➤ALSTARS Phase 2/3 trial randomized approximately 120 subjects across two COYA 302 regimens and placebo
- ➤Three-tier baseline NfL stratification aims to balance prognostic risk across treatment arms
- ➤COYA 302 remains investigational and is not FDA-approved or approved by any regulatory agency
- ➤ALSTARS primary endpoint measures ALSFRS-R change from baseline through Week 24 versus placebo
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individuals
Get started
Create a free account to read the full story.